AbbVie/Roche’s Venclexta produces complete remission in 10% of hard-to-treat CLL patients

AbbVie/Roche’s Venclexta (venetoclax) has produced a high overall response rate in chronic lymphocytic leukaemia patients with the 17p deletion mutation,